103962-10-3

Basic information

• Product Name: 4-(TRIFLUOROMETHOXY)PHENACYL BROMIDE
• Synonyms: BUTTPARK 35\01-56;2-BROMO-1-[4-(TRIFLUOROMETHOXY)PHENYL]ETHAN-1-ONE;2-BROMO-4'-(TRIFLUOROMETHOXY)ACETOPHENONE;4-(TRIFLUOROMETHOXY)PHENACYL BROMIDE;2-brom-4'-(trifluormethoxy)-acetophenon;4-(Trifluoromethoxy)phenacyl bromide 97%;4-(Trifluoromethoxy)phenacylbromide97%;1,1,1-Trifluoromethoxypent-3-en-2-one
• CAS NO: 103962-10-3
• Molecular Formula: C₉H₆BrF₃O₂
• Molecular Weight: 283.04
• Product Categories: Building Blocks;C9;Carbonyl Compounds;Chemical Synthesis;Ketones;Organic Building Blocks;Fluorine series
• Mol File: 103962-10-3.mol
• Article Data: 12

Chemical Properties

• Melting Point: 55 °C
• Boiling Point: 266 °C at 760 mmHg
• Flash Point: 110 °C
• Appearance: Pale yellow/Solid
• Density: 1.621 g/cm³
• Storage Temp.: 2-8°C
• Solubility: Chloroform (Sparingly), Methanol (Slightly)
• CAS DataBase Reference: 4-(TRIFLUOROMETHOXY)PHENACYL BROMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(TRIFLUOROMETHOXY)PHENACYL BROMIDE(103962-10-3)
• EPA Substance Registry System: 4-(TRIFLUOROMETHOXY)PHENACYL BROMIDE(103962-10-3)

Safety Data

• Hazard Codes: C,Xi
• Statements: 34-36/37/38-36
• Safety Statements: 26-36/37/39
• RIDADR: 1759
• WGK Germany: 3
• HazardClass: CORROSIVE
• Hazardous Substances Data: 103962-10-3(Hazardous Substances Data)

Usage

Description

4-(TRIFLUOROMETHOXY)PHENACYL BROMIDE is an organic chemical compound with the molecular formula C8H4BrF3O2. It is a halogenated aromatic compound that features a trifluoromethoxy group attached to a phenacyl bromide moiety. 4-(TRIFLUOROMETHOXY)PHENACYL BROMIDE is known for its reactivity and is commonly used as a synthetic intermediate in various chemical reactions.

Uses

Used in Pharmaceutical Industry:
4-(TRIFLUOROMETHOXY)PHENACYL BROMIDE is used as a synthetic intermediate for the preparation of aminothiazoles, which are therapeutic leads for prion diseases. Prion diseases are a group of rare, progressive neurodegenerative disorders that affect both humans and animals. Aminothiazoles have shown potential in the development of treatments for these diseases due to their ability to inhibit the formation of abnormal prion proteins.
Additionally, 4-(TRIFLUOROMETHOXY)PHENACYL BROMIDE is used in the synthesis of pyrrolidino-tetrahydroisoquinolines. These compounds have demonstrated potent dual H3 antagonist and serotonin transporter inhibitory properties. The H3 receptor is a target for the treatment of various neurological and cognitive disorders, while the serotonin transporter plays a crucial role in the regulation of mood and anxiety. Pyrrolidino-tetrahydroisoquinolines, therefore, have potential applications in the development of medications for conditions such as Alzheimer's disease, schizophrenia, and major depressive disorder.

InChI:InChI=1S/C9H6BrF3O2/c10-5-8(14)6-1-3-7(4-2-6)15-9(11,12)13/h1-4H,5H2

Upstream product

• 85013-98-5 1-[4-(trifluoromethoxy)phenyl]ethan-1-one 

Downstream Products

• 643012-93-5 4-({(4-chlorophenyl)-[4-(4-trifluoromethoxyphenyl)thiazol-2-yl]amino}methyl)benzoic acid 
• 890038-16-1 2-[(3,4-difluorobenzyl)-(2-hydroxyethyl)-amino]-1-(4-trifluoromethoxyphenyl)-ethanone 
• 1196484-40-8 C₄₁H₄₃F₃N₆O₈S₂ 
• 1531649-92-9 2-methyl-4-(4-(trifluoromethoxy)phenyl)oxazole 
• 1531650-13-1 C₁₂H₁₀F₃NO₂ 
• 1403880-69-2 3-(1-(5-bromo-4-(4-(trifluoromethoxy)phenyl)oxazol-2-yl)ethoxy)-2,6-difluorobenzamide 
• 1403880-74-9 3-(1-(5-chloro-4-(4-(trifluoromethoxy)phenyl)oxazol-2-yl)ethoxy)-2,6-difluorobenzamide 
• 1531650-64-2 thiazol-5-yl 
• 1531650-62-0 thiazol-5-yl 
• 1531650-61-9 3-((5-bromo-4-(4-(trifluoromethoxy)phenyl)oxazol-2-yl)methoxy)-2,6-difluorobenzamide 
• 1531650-60-8 thiazol-5-yl 
• 1531650-09-5 C₁₁H₆F₃I₂NO₂ 
• 1531650-08-4 C₁₁H₇F₃INO₂ 
• 1531650-07-3 C₁₁H₆Cl₂F₃NO₂ 

Relevant articles and documents

Based on isoxazole substitution of benzamide derivatives and anti-prostate cancer drug applications

The present invention discloses a class (I), formula (II) structure based on isoxazole substituted benzamide derivatives and antiprostate cancer drug applications, such isoxazole substituted benzamide derivatives, can effectively inhibit the activity of a

Usnic Acid Enaminone-Coupled 1,2,3-Triazoles as Antibacterial and Antitubercular Agents

(+)-Usnic acid, a product of secondary metabolism in lichens, has displayed a broad range of biological properties such as antitumor, antimicrobial, antiviral, anti-inflammatory, and insecticidal activities. Interested by these pharmacological activities and to tap into its potential, we herein present the synthesis and biological evaluation of new usnic acid enaminone-conjugated 1,2,3-triazoles 10-44 as antimycobacterial agents. (+)-Usnic acid was condensed with propargyl amine to give usnic acid enaminone 8 with a terminal ethynyl moiety. It was further reacted with various azides A1-A35 under copper catalysis to give triazoles 10-44 in good yields. Among the synthesized compounds, saccharin derivative 36 proved to be the most active analogue, inhibiting Mycobacterium tuberculosis (Mtb) at an MIC value of 2.5 μM. Analogues 16 and 27, with 3,4-difluorophenacyl and 2-acylnaphthalene units, respectively, inhibited Mtb at MIC values of 5.4 and 5.3 μM, respectively. Among the tested Gram-positive and Gram-negative bacteria, the new derivatives were active on Bacillus subtilis, with compounds 18 [3-(trifluoromethyl)phenacyl] and 29 (N-acylmorpholinyl) showing inhibitory concentrations of 41 and 90.7 μM, respectively, while they were inactive on the other tested bacterial strains. Overall, the study presented here is useful for converting natural (+)-usnic acid into antitubercular and antibacterial agents via incorporation of enaminone and 1,2,3-triazole functionalities.

METALLOENZYME INHIBITOR COMPOUNDS

Provided are compounds having HDAC6 modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by HDAC6.